An experimental study of the influence of antifibrinolytic therapy on post-subarachnoid-hemorrhagic cerebral vasospasm and hydrocephalus.
The incidence and severity of cerebral vasospasm and hydrocephalus following induced subarachnoid hemorrhage in an experimental group of animals that subsequently received epsilon-aminocaproic acid was compared to that seen in a control group that received no antifibrinolytic therapy. No augmentation of either vasospasm or hydrocephalus could be attributed to the epsilon-aminocaproic acid in the treated as compared to the control group.
D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000818:Animals; D002533:Cerebral Angiography; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy*; D006849:Hydrocephalus / Q000150:complications / Q000188:drug therapy*; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy*; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000150:complications* / Q000188:drug therapy; D014057:Tomography, X-Ray Computed
D000614:Aminocaproates; D015119:Aminocaproic Acid